행사 소개
What To Expect At The World Bispecific & T-Cell Engager Summit South Korea
The bispecific & T Cell Engager space is buzzing with innovation aimed at expanding the therapeutic window through improving next-generation designs. Innovation is rife within Asia, with companies such as ABL Bio, Novelty Nobility & Harbour Biomed capturing international attention and investment.
To accelerate this momentum, the inaugural World Bispecific & T-Cell Engager Summit South Korea will bring together global pioneers for the first and only industry-dedicated event in Korea focused on Bispecifics and TCEs. The program has been designed to spotlight co-stimulatory approaches, conditional activation, trispecifics and tetraspecifics, advanced antibody engineering, bispecific ADCs, novel targets, translational biology, T-Cell engagers in autoimmune disease, showcase clinical readouts, and more.
Whether you’re taking candidates to clinic, accelerating your bispecific pipeline, or seeking global partnerships, join 80+ Directors, Heads, and Scientists to gain a holistic perspective and stay ahead in Asia’s fast-growing bispecific and T-Cell engager market and deliver more targeted, efficacious, and safer therapies for patients.
This event is part of the World Targeted Therapeutics Summit South Korea, so attendees will also have access to sessions for the 5th World ADC South Korea Summit and the inaugural World TPD & Induced Proximity Summit South Korea.